Immunomodulatory peptides are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, gastroenterology, ophtalmology and respiratory care.
EVO-003
EVO-003 is EVORA Biosciences’ lead asset. A novel, patent-protected peptide which exhibits strong anti-inflammatory potency alongside a very favorable profile for development as an immunomodulatory drug.
- Selective anti-inflammatory effect
- Stable
- Non-toxic
- Amenable to multiple formulation options
ARDS
ARDS stands for Acute Respiratory Distress Syndrome. The lungs become inflamed for various reasons (virus, infection, trauma,…) and the patient’s immune system turns against them. The initial symptoms are breathing difficulties which may require external mechanical breathing support.
- 4 in 10 patients who suffer from ARDS do not survive.
- Patients suffering from ARDS represent 10% of all Intensive Care Units (ICU) admissions.
- There is currently no approved treatment for ARDS.
- In vivo results support a strong positive recovery from ARDS symptoms thanks to EVO-003.
Management
Hadrien Lanvin, MSc
CEO
CEO
Anna Kostrzak, PhD
Head of R&D
Head of R&D
Directors
Hadrien Lanvin, MSc
CEO EVORA
CEO EVORA
Bruno Toque, PhD
Ex-Founder, CEO Exonhit Therapeutics
Ex-Founder, CEO Exonhit Therapeutics
Philippe Rousseau, MSc
CEO Xenothera
CEO Xenothera
Rémi Gloeckler, PhD
Ex-VP Industrial Partnerships, Ex-VP Industrial Operations
Transgene
Ex-VP Industrial Partnerships, Ex-VP Industrial Operations
Transgene
Partners Network
EVORA Biosciences is supported by
contact@evorabio.com
© EVORA Biosciences 2024